Search Clinical Trials
583,298 trials
ID
Status
Phase
Title
Sponsor
NCT07570290
Comparison of Artificial Intelligence and Clinicians With Different Experience Levels in Assessing Gingival PhenotypeOndokuz Mayıs UniversityNot Yet Recruiting
NCT07570290Not Yet Recruiting
—
Comparison of Artificial Intelligence and Clinicians With Different Experience L...Ondokuz Mayıs University
NCT07569744
Resveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 DiabetesUniversitas SriwijayaNot Yet RecruitingNot Applicable
NCT07569744Not Yet Recruiting
Not Applicable
Resveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 DiabetesUniversitas Sriwijaya
NCT07569601
The Effect of Heat Pads and Foam Rolling on Strength in Athletes.University of RedlandsActive Not RecruitingNot Applicable
NCT07569601Active Not Recruiting
Not Applicable
The Effect of Heat Pads and Foam Rolling on Strength in Athletes.University of Redlands
NCT07568639
Multi-Site Cortical Puncture for DORFirst Affiliated Hospital of Guangxi Medical UniversityNot Yet RecruitingNot Applicable
NCT07568639Not Yet Recruiting
Not Applicable
Multi-Site Cortical Puncture for DORFirst Affiliated Hospital...
NCT07568574
Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesEnhanced Emirates LimitedEnrolling By InvitationNot Applicable
NCT07568574Enrolling By Invitation
Not Applicable
Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite A...Enhanced Emirates Limited
NCT07570927
Salivary Microbiota and Antimicrobial Resistance in Relation to Chlorhexidine UseMasaryk UniversityCompletedNot Applicable
NCT07570927Completed
Not Applicable
Salivary Microbiota and Antimicrobial Resistance in Relation to Chlorhexidine Us...Masaryk University
NCT07570836
Safety and Preliminary Efficacy of hUCMSC-EVs in Interstitial Lung DiseaseShanghai Zhongshan HospitalNot Yet RecruitingPhase 1
NCT07570836Not Yet Recruiting
Phase 1
Safety and Preliminary Efficacy of hUCMSC-EVs in Interstitial Lung DiseaseShanghai Zhongshan Hospit...
NCT07570589
An Observational, Prospective, Multicenter, Open-label Study to Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)Centre Hospitalier Universitaire de NiceNot Yet Recruiting
NCT07570589Not Yet Recruiting
—
An Observational, Prospective, Multicenter, Open-label Study to Monitor the Evol...Centre Hospitalier Univer...
NCT07571174
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral SclerosisEli Lilly and CompanyNot Yet RecruitingPhase 1
NCT07571174Not Yet Recruiting
Phase 1
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclero...Eli Lilly and Company
NCT07571681
Colchicine for Autoimmune and Subacute ThyroiditisMansoura UniversityNot Yet RecruitingPhase 2
NCT07571681Not Yet Recruiting
Phase 2
Colchicine for Autoimmune and Subacute ThyroiditisMansoura University
NCT07570862
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisFate TherapeuticsNot Yet RecruitingPhase 2
NCT07570862Not Yet Recruiting
Phase 2
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Neph...Fate Therapeutics
NCT07569458
Online Personalized Psychological Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE)Aalborg University HospitalRecruitingNot Applicable
NCT07569458Recruiting
Not Applicable
Online Personalized Psychological Intervention for Patients With Heart Disease a...Aalborg University Hospit...
NCT07569536
Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic ShockCentre Hospitalier Universitaire DijonNot Yet RecruitingPhase 3
NCT07569536Not Yet Recruiting
Phase 3
Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in...Centre Hospitalier Univer...
NCT07570849
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic CholangiocarcinomaShanghai Zhongshan HospitalRecruitingPhase 2
NCT07570849Recruiting
Phase 2
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment f...Shanghai Zhongshan Hospit...
NCT07571213
Pre-ICU Hospital Length of Stay and 30-day Mortality in the Very Old: a National Cohort of 315 042 ICU AdmissionsRegion DalarnaCompleted
NCT07571213Completed
—
Pre-ICU Hospital Length of Stay and 30-day Mortality in the Very Old: a National...Region Dalarna
NCT07571369
Stress Modulation and Dynamic BalanceKafrelsheikh UniversityNot Yet RecruitingNot Applicable
NCT07571369Not Yet Recruiting
Not Applicable
Stress Modulation and Dynamic BalanceKafrelsheikh University
NCT07570186
Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male ParticipantsOnconic Therapeutics Inc.Not Yet RecruitingPhase 1
NCT07570186Not Yet Recruiting
Phase 1
Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy...Onconic Therapeutics Inc.
NCT07571902
Revised-Paravertebral Nerve Blocks for Enhanced Recovery After Stoma ClosureSixth Affiliated Hospital, Sun Yat-sen UniversityNot Yet RecruitingNot Applicable
NCT07571902Not Yet Recruiting
Not Applicable
Revised-Paravertebral Nerve Blocks for Enhanced Recovery After Stoma ClosureSixth Affiliated Hospital...
NCT07569783
tDCS for Reducing the Incidence of OEI After Cesarean SectionAffiliated Hospital of Nantong UniversityNot Yet RecruitingNot Applicable
NCT07569783Not Yet Recruiting
Not Applicable
tDCS for Reducing the Incidence of OEI After Cesarean SectionAffiliated Hospital of Na...
NCT07571473
CoreSys Monitoring for Intraoperative Stress Management in Abdominal HysterectomyCoresys HealthRecruitingNot Applicable
NCT07571473Recruiting
Not Applicable
CoreSys Monitoring for Intraoperative Stress Management in Abdominal Hysterectom...Coresys Health
Result Breakdown
Not yet recruiting13 (65%)
Recruiting3 (15%)
Completed2 (10%)
Active, not recruiting1 (5%)
Enrolling by invitation1 (5%)
not_applicable10 (50%)
Not Specified3 (15%)
Phase 13 (15%)
Phase 23 (15%)
Phase 31 (5%)